Ben Smail D, Peskine A, Roche N, Mailhan L, Thiébaut I- B, Bussel B
Service de Médecine Physique et Readaptation, Hôpital R. Poincaré, 104 Bd R. Poincaré, 92380 Garches, France.
Mult Scler. 2006 Feb;12(1):101-3. doi: 10.1191/1352458506ms1232sr.
We conducted a retrospective study of the case files of 64 multiple sclerosis (MS) patients presenting severe spasticity, who had received intrathecal (IT) baclofen test injections between 1992 and 2004 in a rehabilitation unit. In almost all cases of our series, IT baclofen was proposed to patients who were no longer able to walk. IT baclofen is a safe and effective treatment to reduce spasticity in MS patients. Despite an advanced stage of the disease at the time of pump placement, the complication rate was low and the efficacy of this treatment was maintained over time.
我们对64例患有严重痉挛的多发性硬化症(MS)患者的病历进行了回顾性研究,这些患者于1992年至2004年期间在一家康复机构接受了鞘内注射巴氯芬试验性注射。在我们系列研究的几乎所有病例中,鞘内注射巴氯芬是针对那些已无法行走的患者提出的。鞘内注射巴氯芬是一种安全有效的治疗方法,可减轻MS患者的痉挛。尽管在植入泵时疾病已处于晚期,但并发症发生率较低,且这种治疗的疗效随时间得以维持。